SARomics Biostructure’s fragment screening services are part of our broader structural biology and drug discovery offerings. Our advanced technology platform offers a range of biophysical fragment screening methods, including NMR- and crystallographic fragment screening, and our proprietary weak-affinity chromatography screening. Our proprietary fragment libraries and our library of 600+ off-the-shelf proteins enable rapid screening and co-crystallization of new hits with the drug target. Our fragment screening group collaborates closely with the medicinal chemistry team at RG Discovery to deliver a comprehensive, well-integrated fragment-based drug discovery and design (FBDD) process. We focus on driving the project from initial hit identification through hit expansion, lead generation, and optimization. Ultimately, our goal is to nominate the most promising candidate drug for further trials.
